Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | -0.22 | $0 | -$6M |
| 2025 Q2 | -0.10 | $0 | -$7M |
| 2024 Q4 | -0.13 | $0 | -$2M |
| 2024 Q2 | -0.18 | $0 | $304,943 |
| 2023 Q4 | -0.18 | $0 | -$3M |
| 2023 Q2 | -0.20 | $0 | -$9M |
| 2022 Q4 |
| -0.28 |
| $0 |
| -$6M |
| 2022 Q2 | -0.10 | $0 | -$10M |